N-叔丁基-α-苯基硝酮
| 中文名称 | N-叔丁基-α-苯基硝酮 |
|---|---|
| 中文同义词 | N-苯亚甲基叔丁胺-N-氧化物;N-叔丁基-Α-苯基硝酮;N-叔丁基-Α-苯基硝酸灵;N-叔丁基-Α-苯基硝酮,98%;N-叔丁基-Α-苯基硝酸酮;N-叔丁基-A-苯硝酮;N-叔丁基-а-苯基硝酮;叔丁基(亚苄基)胺 N-氧化物 |
| 英文名称 | N-TERT-BUTYL-ALPHA-PHENYLNITRONE |
| 英文同义词 | c-phenyl-n-tert-butylnitrone;n-benzylidene-tert-butylamineoxide;n-tert-butyl-2-phenylnitrone;n-tert-butyl-alpha-phenyl-nitron;n-tert-butyl-c-phenylnitrone;(Z)-N-benzylidene-2-Methylpropan-2-aMine oxide;PHENYL N-TERT-BUTYLNITRONE;PBN |
| CAS号 | 3376-24-7 |
| 分子式 | C11H15NO |
| 分子量 | 177.24 |
| EINECS号 | 222-168-6 |
| 相关类别 | 生化试剂;合成材料中间体;有机化工原料;酶与辅酶;Spin Trapping Reagents;Analytical Chemistry;ESR Spectrometry |
| Mol文件 | 3376-24-7.mol |
| 结构式 |  |
N-叔丁基-α-苯基硝酮 性质
| 熔点 | 73-74 °C(lit.) |
|---|---|
| 沸点 | 283℃ |
| 密度 | 0.990 |
| 折射率 | 1.5480 (estimate) |
| 闪点 | 119℃ |
| 储存条件 | Store at <= 20°C. |
| 溶解度 | 可溶于DMSO |
| 形态 | 粉末 |
| 酸度系数(pKa) | 1.50±0.53(Predicted) |
| 颜色 | 白色 |
| 水溶解性 | Soluble in DMSO (10 mg/ml), chloroform (50 mg/ml), and water (20 mg/ml). |
| Merck | 14,7056 |
| BRN | 2044028 |
| 化妆品成分功效 | ANTIOXIDANT |
| InChI | 1S/C11H15NO/c1-11(2,3)12(13)9-10-7-5-4-6-8-10/h4-9H,1-3H3/b12-9- |
| InChIKey | IYSYLWYGCWTJSG-XFXZXTDPSA-N |
| SMILES | CC(C)(C)[N+](\[O-])=C\c1ccccc1 |
| CAS 数据库 | 3376-24-7(CAS DataBase Reference) |
| EPA化学物质信息 | 2-Propanamine, 2-methyl-N-(phenylmethylene)-, N-oxide (3376-24-7) |
|
COX-2
|
Reactive oxygen species (ROS)
|
N-tert-Butyl-α-phenylnitrone (PBN) (25-100 µM) treatment leads to a significant decrease in 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced intracellular ROS accumulation. N-tert-Butyl-α-phenylnitrone also attenuates AAPH-induced cytotoxicity, matrix degradation, and apoptosis. N-tert-Butyl-α-phenylnitrone suppresses AAPH-induced activation of ERK/MAPK pathway. N-tert-Butyl-α-phenylnitrone has the potenial for intervertebral disc degeneration (IDD) research.
N-tert-Butyl-α-phenylnitrone (PBN; 100 mg/kg; intraperitoneal injection; twice a day; C57Bl/6 mice) treatment not only abolishes the LPS-induced lipid peroxidation, nitrotyrosine residue levels, and GSH depletion, but also decreases the incidence of external malformations.
| Animal Model: | C57Bl/6 mice induced by lipopolysaccharide (LPS) |
| Dosage: | 100 mg/kg |
| Administration: | Intraperitoneal injection; twice a day (on gestational day 8) |
| Result: | Abolished LPS-induced lipid peroxidation, nitrotyrosine residues, and GSH depletion. |
| 提供商 | 语言 |
|---|---|
|
英文
|
|
|
英文
|
|
|
中文
|
|
|
英文
|